Circle RNA circABCB10 Modulates PFN2 to Promote Breast Cancer Progression, as Well as Aggravate Radioresistance Through Facilitating Glycolytic Metabolism Via miR-223-3p.

Cancer Biotherapy & Radiopharmaceuticals
Yue ZhaoZhenlin Zhou

Abstract

Background: Breast cancer (BC) is a common tumor in women worldwide, and irradiation (IR) resistance is a major obstacle for BC therapy. Circle RNAs (circRNAs) were identified as implicated in the progression of cancer and IR resistance. However, the role of circABCB10 in BC progression and IR resistance is not well defined. Materials and Methods: The levels of circABCB10, miR-223-3p, and profilin-2 (PFN2) were detected by quantitative real-time polymerase chain reaction. The cell viability and survival rate were monitored by MTT assay. The glucose consumption, lactic acid production, LDH-A activity, and ATP production were evaluated to measure glycolysis. The protein levels of hypoxia inducible factor-1α (HIF-1α), hexokinase 2 (HK2), lactate dehydrogenase A chain (LDH-A), and PFN2 were estimated by Western blot assay. The colony formation rate was tested by colony formation assay. Dual-luciferase reporter assay was constructed to validate the interaction between miR-223-3p and circABCB10 or PFN2. The mice xenograft assay was performed to further verify the effects of circABCB10 on BC progression in vivo. Results: CircABCB10 and PFN2 were elevated, while miR-223-3p was reduced in BC tissues and cells. CircABCB10 sponged miR-223...Continue Reading

References

Sep 17, 2004·Nature·Victor Ambros
Aug 9, 2007·Reviews of Physiology, Biochemistry and Pharmacology·B M JockuschM Rothkegel
May 23, 2009·Science·Matthew G Vander HeidenCraig B Thompson
Dec 17, 2009·Journal of Cancer Research and Therapeutics·B S DwarakanathViney Jain
Nov 16, 2011·Cancer Research·Franziska HirschhaeuserWolfgang Mueller-Klieser
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Aug 26, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Tsutomu ShimuraNaoki Kunugita
Oct 3, 2015·Oncotarget·Zhiyu WangHonglin Situ
Jan 19, 2016·Trends in Biochemical Sciences·Maria V Liberti, Jason W Locasale
Mar 25, 2016·Cancer Chemotherapy and Pharmacology·Fei ZhaoLinjun Fan
May 18, 2016·The Journal of Investigative Dermatology·York KamenischMark Berneburg
Feb 2, 2017·Molecular Cancer·Yumin WangWei Xiong
Dec 19, 2017·The Breast : Official Journal of the European Society of Mastology·Jason C Ye, Silvia C Formenti
Feb 8, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Yanfang YangLin Gu
Apr 4, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Hang YinQingyong Xu
Feb 14, 2019·Journal of Experimental & Clinical Cancer Research : CR·Peng LuoBaolong Wang

❮ Previous
Next ❯

Citations

Mar 23, 2021·Clinica Chimica Acta; International Journal of Clinical Chemistry·Bowen LiuYunfu Cui
Apr 16, 2021·OncoTargets and Therapy·Tan LiXin-Hua Liang

❮ Previous
Next ❯

Datasets Mentioned

BETA
MDA-MB-453

Methods Mentioned

BETA
PCR
X-ray
transfection
Assay
xenograft

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.